Dr. Lana Janes is a biopharmaceutical industry veteran with over 20 years of pharmaceutical development experience that spans the full life cycle of therapeutic product development. She is currently a Venture Partner at adMare BioInnovations where she focusses on identifying compelling areas of strategic commercial opportunity, and driving the creation and acceleration of new companies for Canada’s life science sector. Before joining adMare, Lana served as Senior Vice President, Intellectual Property and Technology Development and Chief Patent Officer at QLT Inc. where, for twelve years, she oversaw all aspects of global R&D and IP strategy for the company’s commercial, clinical and pre-clinical stage therapeutic programs. She has also served as COO of Retinagenix Therapeutics, a Seattle-based privately held ophthalmology company focused on rare diseases of the retina. Earlier in her career, Lana worked as a registered Canadian and US patent agent in the Toronto office of Ogilvy Renault LLP (now Norton Rose Fulbright) and at F. Hoffman-La Roche in Basel, Switzerland, where her practice focussed on the strategic IP and regulatory protection for numerous therapeutic and medical device products. Lana sits on the Boards of Directors for several entrepreneurial start-up biotechs in Vancouver, and is an associate at Creative Destruction Labs in Vancouver, providing her with valuable experience and insight in strategically and cost-effectively advancing pre-IND stage and semi-virtual companies. Lana received her AB in Chemistry with honors from Harvard University and her Ph.D. in organic chemistry from McGill University, where she also conducted post-doctoral work in the field of antiviral therapeutics. She also worked for several years as a synthetic organic chemist in the chemical and food industries in the US and UK.